Trends in Molecular Medicine
OpinionTherapeutic potential of LIF in multiple sclerosis
Section snippets
Neuroprotective therapies are needed for multiple sclerosis (MS)
MS is the most common cause of nontraumatic neurological disability in North America and Europe. Most patients initially develop a relapsing–remitting form of the disease (RRMS), characterized by episodes of neurological disability followed by episodes of improvement. After 8 to 20 years, the majority of patients with RRMS develop secondary progressive MS. In this stage, patients usually suffer few if any attacks but accumulate neurological disability. Approximately 15% of patients are
LIF as part of the endogenous biological response to protect the CNS
LIF is undetectable in the healthy nervous system, but its expression increases after different types of neuronal distress, including nerve injury, ischemia, spinal cord injury, in MS lesions, in the hippocampus of patients with Alzheimer's or Parkinson's disease and after seizure 2, 4, 5, 6, 7, 8, 9. It has therefore been hypothesized that the activation of LIF signaling is part of an endogenous neurobiological response that limits nerve injury. Indeed, LIF can protect neurons and
Immunomodulatory properties of LIF
Although the protective effects of LIF on neurons and oligodendrocytes make it a good therapeutic option for MS, its immunomodulatory properties are also relevant, especially when considering LIF administration in a chronic autoimmune disease such as MS. LIF has proinflammatory effects in rheumatoid arthritis, during cutaneous inflammation and after overexpression in the mouse spinal cord 30, 31, 32. In arthritis models, LIF activates osteoclast activity, thereby inducing bone resorption and
Regeneration and repair
It was once believed that damaged neurons could not be replaced, making neurodegeneration in MS a detrimental and irreversible event. We now know that multipotent neural stem cells (NSCs) persist in the adult brain, but their contributions to repair after brain injury are limited. Stimulation of the regenerative potential of endogenous progenitors with appropriate signals could be of therapeutic value. Interestingly, LIF prevents the differentiation of embryonic stem (ES) cells by promoting
Therapeutic implications and concluding remarks
In vitro and in vivo animal studies have provided exciting new insights into the protective effects of LIF during neuroinflammation, but two important concerns, safety and efficacy, remain hurdles for the application of LIF in the clinic. A phase I safety study with recombinant human LIF (rhLIF), AM424 (AMRAD Operations, Australia), has been completed in patients with advanced cancer [65]. LIF, ranging from 0.25 to 16 μg/kg body weight, was administered subcutaneously on a daily basis after
References (82)
Leukemia inhibitory factor is expressed in astrocytes following cortical brain injury
Exp. Neurol.
(1997)Leukaemia inhibitory factor (LIF) production in a mouse model of spinal trauma
Neurosci. Lett.
(1998)Expression of cytokines and cytokine receptors in the rat brain after kainic acid-induced seizures
Brain Res. Mol. Brain Res.
(2003)Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor
Neuroscience
(2006)Astrocytes promote myelination in response to electrical impulses
Neuron
(2006)- et al.
Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse
Exp. Neurol.
(2004) Endogenous leukemia inhibitory factor attenuates endotoxin response
Lab. Invest.
(2005)Leukemia inhibitory factor modulates production of inflammatory mediators and myelin phagocytosis by macrophages
J. Neuroimmunol.
(2008)Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls
J. Neuroimmunol.
(2006)Disturbed regulatory T cell homeostasis in multiple sclerosis
Trends Mol. Med.
(2010)